KEYNOTE-966 Long-Term Follow-Up and Comparative Safety of Chemoimmunotherapy

The panel reviews the KEYNOTE-966 long-term follow-up data. With long-term follow-up, the addition of pembrolizumab to gemcitabine and cisplatin maintained a clinically meaningful overall survival benefit with no new safety signals. The faculty discuss how this data relates to the TOPAZ-1 study and how it compares to practice. In TOPAZ-1, grade 3 or 4 adverse events were similar between arms, discontinuation due to adverse events was comparable, the most common events were hematologic and attributable to the chemotherapy backbone, and immune-mediated adverse events occurred more often with durvalumab but were generally manageable. In KEYNOTE-966, overall grade 3 or 4 adverse event rates were comparable between arms, the most common events were again cytopenias consistent with chemotherapy backbone, and immune-mediated adverse events and infusion reactions occurred more often with pembrolizumab, most commonly hypothyroidism and pneumonitis. The faculty close with practical counseling strategies.